According to the World Health Organization (WHO), more than 33 million people are living with HIV worldwide and 2.7 million people are newly infected each year. Sub-Saharan Africa alone accounts for two-thirds of the epidemic.

Gilead recognizes the urgent global need for access to HIV medications, particularly in resource-limited countries where the epidemic has hit the hardest. Since our first HIV product, Viread, reached the market in 2001, we have focused on expanding access to our portfolio of HIV medications. Today, more than 700,000 patients in the developing world are receiving Viread or Viread-containing products.

Our efforts are guided by the following principles:

• Antiretroviral products for the developing world should be of same quality as those sold in wealthy nations.
• Tiered pricing for antiretroviral products, reflecting each country's economic status and disease prevalence, is an essential tool for broadening access.
• Partnerships - government, industry, academic and community - are critical for success.

Gilead's programs and partnerships also help to provide support for people living with HIV/AIDS. Gilead has made a commitment to make Viread and Truvada available for treatment and prevention research in the developing world, and we are currently involved in more than 50 studies which have enrolled more than 27,800 patients in Africa, Asia and Latin America.

To learn more about Gilead's commitment to addressing HIV/AIDS, click on the links below:

• Partnerships
• Enabling Access to Treatment
• Product Registration